Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes

March 31, 2020 updated by: Alessandro Cucchi, GBR Academy

Guided Bone Regeneration With Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes.

The objective of this study is to compare two surgical techniques for the treatment of the mandibular bone atrophies: Dense PTFE titanium-reinforced membranes (Group A) versus Titanium mesh covered with cross-linked collagen membranes (Group B).

Therefore, the main purposes are to compare test and control regarding (i) the percentage of post-operative complications (ii) the three-dimensional bone gain (iii) histological, histomorphometrical and microCT outcomes (iv) perImplant bone loss and soft tissue parameters.

Study Overview

Detailed Description

In the last 10 years, short- and long-term studies have demonstrated that GBR is a successful and reliable technique for vertical and horizontal ridge augmentation. GBR can be achieved with two different approaches: application of either a polytetrafluoroethylene (PTFE) titanium-reinforced membrane (i.e., a non-resorbable membrane) or a collagen membrane (i.e., a resorbable membrane). To achieve vertical bone augmentation, a resorbable membrane must be supported by a space-making device, such as a titanium mesh (Ti mesh) or a titanium osteosynthesis plate.

However, the use of a barrier device is a technique-sensitive procedure that is not free of complications. The main cause of GBR failure is related to early or late exposure of a barrier device, leading to contamination and infection of the biomaterial, irreversibly compromising bone regeneration.

This study aims to evaluate complication rates and vertical bone gain (VBG) after GBR with dense PTFE titanium-reinforced membranes versus with titanium mesh covered with cross-linked collagen membranes.

The primary objective of the study is, therefore, the evaluation of the healing complications; in particular, the early or delayed exposure of medical devices used for bone regeneration, during the healing period. This exposure is, as reported in all clinical studies, the main cause of the failure of the surgery. A secondary objective, is the quantitative assessment of bone regeneration obtained by the 2 techniques. In particular, the evaluation of the reconstructed bone volume (RBV) with respect to the planned bone volume (PBV). Other targets include the qualitative evaluation of bone regeneration through histological and histomorphometric analysis of the bone biopsies obtained at the moment that the medical device is removed and finally the evaluation of the peri-implant bone resorption will be conducted over time. This study was designed as a pilot, parallel-group, double-blind, randomized, comparative clinical trial. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethical Committee of the Sant'Orsola-Malpighi Hospital (Prot. CMF 01/2013; number 30/2013/O/Disp).

The study included 40 patients with partial edentulism, associated with alveolar atrophy in the posterior regions of the mandible, who were referred to the Unit of Oral and Maxillofacial Surgery, Alma Mater Studiorum, University of Bologna, Italy.

Patients were randomized into two study groups, depending on a previous computer-generated randomization sequence. Group A included 20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane, and Group B included 20 patients treated by means of a titanium mesh (Ti mesh) and cross-linked collagen membrane.

The study included 3 different treatment phases: the first phase (T0) involves bone regeneration with Dense PTFE titanium-reinforced membranes (Group A) or Titanium mesh covered with cross-linked collagen membranes (Group B) and simultaneous implants placement; the second one (T1), subsequently, after 6 months, this will forsee the removal of the regeneration devices; the third (T2), 3 months after the aforementioned, will forsee the final functional loading of the implants, with a consequent follow-up of the regenerated bone. All the materials and tools used in the study are CE certified and have already been used in the normal care path for patients who have undergone bone regeneration. Moreover, the control visits and the radiological investigations of the data were summarized in the case report form (CRF), and are those that characterize the normal care path of patients undergoing necessary bone regeneration for prosthetic implant rehabilitation when the bone quantity is insufficient.

The primary objective of this study is to evaluate the non-inferiority of group B (Ti mesh) compared to technique A (d-PTFE membrane) in the incidence of complications. The Secondary objectives include: assessment of reconstructed bone volume (RBV) compared to planned bone volume (PBV), histological and histomorphometric analysis of bone quality obtained and periimplant bone resorption after 12 months of follow-up.

The sample size calculation showed that with a minimum of 17 patients per group (total of 34 patients), it will be possible to detect a 35% difference in complications and a difference of 1 mm in VBG between the two groups with a standard deviation a=1 and a significance level of a = 0.05 with a power of 80%. To protect from possible drop-outs, the sample size was increased by to 20 patients per group (total of 40 patients).

The results obtained in the two study groups (Groups A and B) were subjected to statistical description and analyses using specific tests to determine statistically significant differences between them. Both the intent-to-treat and per-protocol populations were analyzed. The patient was regarded as the statistical unit of analysis for all analyses, except that of implant stability, which was carried out considering the implant as the statistical unit. Statistical differences in complication rates were investigated using Fisher's exact test. Differences in implant stability, peri-implant bone defects, and VBG at T0 and T1 were investigated using t-tests for unpaired data. Statistical significance was set at α = 0.05. The statistician was blinded and external to working group.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bologna, Italy, 40126
        • School of Dentistry - University of Bologna

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • edentulism in posterior regions of the mandible with vertical and horizontal bone resorption of the alveolar ridge requiring three-dimensional bone regeneration and implant-supported rehabilitation
  • a vertical peri-implant bone defect of ≥ 2 mm in the alveolar ridge that must be regenerated after placement of implants in a three-dimensional 'ideal' position;
  • capacity to understand and accept the conditions of the study; and 4 continuing participation in the study for at least 1 year of follow up.

Exclusion Criteria:

  • residual bone height < 5 mm;
  • insufficient oral hygiene;
  • a smoking habit of > 10 cigarettes/day;
  • abuse of alcohol or drugs;
  • pregnancy;
  • acute local or systemic infection;
  • uncontrolled diabetes or other metabolic disease;
  • severe hepatic or renal dysfunction; HIV, HBV, or HCV;
  • chemotherapy or radiotherapy within the last 5 years;
  • immunosuppression therapy;
  • autoimmune disorders;
  • bisphosphonate therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A - control group
20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
Experimental: Group B - Test group
20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The rate of healing complications after reconstructive surgery
Time Frame: 6 months

Healing complications are evaluated based on the chronological order in which they occur:• immediate exposure occurs within the 1st month

  • early exposure occurs between the 1st and the 3rd month
  • late exposure occurs between after the 3rd month Evaluation of low-grade and high-grade infection of medical devices used for bone regeneration.

The former complications are classified as:

  • Class A, including flap damage (soft tissue perforation or laceration)
  • Class B, including neurological damage (paresthesia or disesthesia)
  • Class C,including vascular damage (hemorrhage). The latter complications are divided into four classes, according to the presence and extent of exposure, as well as the presence of a purulent exudate:
  • Class I, membrane exposure <3 mm, no purulent exudate
  • Class II membrane exposure >=3mm, no purulent exudate
  • Class III: membrane exposure, with purulent exudate
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implants Insertion Torque
Time Frame: during surgery
measured with a manual dynamometric torque wrench, able to measure torques up to 100 Ncm
during surgery
Change in implant Stability
Time Frame: during surgery/after 6 months
Change from implant stability during surgery and at 6 months was evaluated using the implant stability quotient recorded during surgery and after 6 months during reopening surgery
during surgery/after 6 months
Vertical bone gain
Time Frame: at 6 months
calculated as the difference between the initial bone defect and the residual bone defect expressed in millimeters (mm).
at 6 months
Bone tissue area (B.ar)
Time Frame: at 6 months
evaluated as the total area of regenerated bone performed with a digital microscopic evaluation.
at 6 months
Bone volume (B.V)
Time Frame: at 6 months
evaluated as the total volume of the regenerated bone performed with a MicroCT evaluation.
at 6 months
Peri-implant bone level (PBL)
Time Frame: at 1 years
was evaluated as the distance between the implant shoulder and the visible bone crest on periapical radiograph using a parallel technique. The distance was measured to the nearest 0.01 mm using an image analysis software (Image J, NIH).
at 1 years
Inter-proximal bone peaks (IBP)
Time Frame: at 1 years
was evaluated as the distance between the interproximal bone peak and the "ideal" regeneration line on periapical radiograph using a parallel technique. The distance was measured to the nearest 0.01 mm using an image analysis software (Image J, NIH)
at 1 years
Probing pocket depth (PPD)
Time Frame: at 1 years
The probing depth was measured from the gingival margin at the base of the groove or pocket in the central and distal mesial sites, using the calibrated Click-probe millimeter probe 3/5/7/10 mm scale
at 1 years
Thickness of keratinized tissue (tKT)
Time Frame: at 1 years
The thickness of the soft tissues was determined apically at the gingival margin using a file for endodontic therapy measures 8 and with a 3 mm diameter silicone disk with a stop function
at 1 years
Width of keratinized mucosa (wKT)
Time Frame: at 1 years
The height of the keratinized mucosa was determined by the gingival margin at the vestibular muco-gingival line
at 1 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Giuseppe Corinaldesi, unibo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2013

Primary Completion (Actual)

September 1, 2016

Study Completion (Actual)

September 1, 2019

Study Registration Dates

First Submitted

March 26, 2020

First Submitted That Met QC Criteria

March 31, 2020

First Posted (Actual)

April 3, 2020

Study Record Updates

Last Update Posted (Actual)

April 3, 2020

Last Update Submitted That Met QC Criteria

March 31, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CMF 01/2013

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Original articles in international journals

IPD Sharing Time Frame

june 2020

IPD Sharing Access Criteria

Access credentials to journal resources

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bone Loss

Clinical Trials on Group A - control group

Subscribe